Lauri Kangas

4.0k total citations
162 papers, 3.3k citations indexed

About

Lauri Kangas is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Lauri Kangas has authored 162 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Genetics, 32 papers in Molecular Biology and 31 papers in Oncology. Recurrent topics in Lauri Kangas's work include Estrogen and related hormone effects (54 papers), Anesthesia and Sedative Agents (27 papers) and Epilepsy research and treatment (19 papers). Lauri Kangas is often cited by papers focused on Estrogen and related hormone effects (54 papers), Anesthesia and Sedative Agents (27 papers) and Epilepsy research and treatment (19 papers). Lauri Kangas collaborates with scholars based in Finland, United States and Canada. Lauri Kangas's co-authors include J Kanto, M. Grönroos, A. L. Nieminen, Risto Erkkola, Pirkko Härkönen, A. Pekkarinen, Ismo Virtanen, Taneli Tani, R. Hiltunen and K. Kahlos and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer.

In The Last Decade

Lauri Kangas

160 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lauri Kangas Finland 31 1.1k 919 657 512 395 162 3.3k
R. De Coster Belgium 29 832 0.7× 713 0.8× 451 0.7× 548 1.1× 136 0.3× 70 2.7k
Seiichiro Tarui Japan 40 804 0.7× 2.0k 2.2× 493 0.8× 1.9k 3.8× 380 1.0× 264 6.6k
Frederick R. DeRubertis United States 47 400 0.4× 2.4k 2.6× 558 0.8× 1.0k 2.0× 330 0.8× 139 6.6k
V.H.T. James United Kingdom 41 2.2k 1.9× 1.3k 1.4× 629 1.0× 2.7k 5.3× 299 0.8× 217 6.1k
Yu‐Jui Yvonne Wan United States 45 784 0.7× 3.1k 3.4× 1.2k 1.8× 432 0.8× 498 1.3× 184 6.3k
Patricia A. Craven United States 43 310 0.3× 2.1k 2.3× 468 0.7× 665 1.3× 331 0.8× 119 5.6k
Jamie D. Croxtall United Kingdom 33 482 0.4× 1.7k 1.8× 357 0.5× 270 0.5× 410 1.0× 74 3.9k
Ruud Berger Netherlands 48 648 0.6× 2.9k 3.2× 1.3k 2.0× 555 1.1× 285 0.7× 152 7.4k
Antonio Morelli Italy 46 418 0.4× 1.1k 1.2× 1.3k 2.0× 217 0.4× 165 0.4× 112 7.3k
Alex Bobik Australia 50 334 0.3× 3.1k 3.3× 402 0.6× 884 1.7× 721 1.8× 226 8.7k

Countries citing papers authored by Lauri Kangas

Since Specialization
Citations

This map shows the geographic impact of Lauri Kangas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauri Kangas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauri Kangas more than expected).

Fields of papers citing papers by Lauri Kangas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauri Kangas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauri Kangas. The network helps show where Lauri Kangas may publish in the future.

Co-authorship network of co-authors of Lauri Kangas

This figure shows the co-authorship network connecting the top 25 collaborators of Lauri Kangas. A scholar is included among the top collaborators of Lauri Kangas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauri Kangas. Lauri Kangas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Kathy, et al.. (2023). Hyperspectral imaging to accurately segment skin erythema and hyperpigmentation in cutaneous chronic graft‐versus‐host disease. Journal of Biophotonics. 16(7). e202300009–e202300009. 7 indexed citations
2.
Polari, Lauri, Sofia Sousa, Lauri Kangas, et al.. (2018). SERMs Promote Anti-Inflammatory Signaling and Phenotype of CD14+ Cells. Inflammation. 41(4). 1157–1171. 19 indexed citations
3.
Kangas, Lauri & Mikko Unkila. (2013). Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications. Steroids. 78(12-13). 1273–1280. 34 indexed citations
4.
Leskelä, Hannu‐Ville, Siri Lehtonen, Anitta Mahonen, et al.. (2006). Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts. Bone. 39(5). 1026–1034. 51 indexed citations
5.
Irjala, Kerttu, Pekka Manninen, Lauri Kangas, et al.. (2001). Pharmacokinetics of finrozole (MPV‐2213ad), a novel selective aromatase inhibitor, in healthy men. British Journal of Clinical Pharmacology. 52(6). 702–704. 8 indexed citations
6.
Karlsson, Stefan, et al.. (1999). The Effect of Toremifene on Bone and Uterine Histology and on Bone Resorption in Ovariectomised Rats. Pharmacology & Toxicology. 84(2). 72–80. 5 indexed citations
7.
Hukkanen, Janne, et al.. (1998). Expression of Cytochrome P450 Genes Encoding Enzymes Active in the Metabolism of Tamoxifen in Human Uterine Endometrium. Pharmacology & Toxicology. 82(2). 93–97. 52 indexed citations
8.
Lohi, Jouni, Matti Korhonen, Ilmo Leivo, et al.. (1997). Expression of type IV collagen α1(IV)–α6(IV) polypeptides in normal and developing human kidney and in renal cell carcinomas and oncocytomas. International Journal of Cancer. 72(1). 43–49. 38 indexed citations
9.
Lipponen, P., et al.. (1997). Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer. Cancer Chemotherapy and Pharmacology. 41(1). 15–21. 6 indexed citations
10.
11.
Baral, Edward, Éva Nagy, Lauri Kangas, & István Berczi. (1996). Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma. International Journal of Cancer. 67(4). 580–585. 6 indexed citations
12.
Berthou, F., et al.. (1994). Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochemical Pharmacology. 47(10). 1883–1895. 75 indexed citations
13.
Mäenpää, Juhani, et al.. (1992). Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecologic Oncology. 46(3). 292–297. 9 indexed citations
14.
Minn, Heikki, Lauri Kangas, Pirkko Kellokumpu‐Lehtinen, et al.. (1992). Uptake of 2-fluoro-2-deoxy-d-[U-14C]-glucose during chemotherapy in murine Lewis lung tumor. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 19(1). 55–63. 11 indexed citations
15.
Kangas, Lauri. (1990). Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemotherapy and Pharmacology. 27(1). 8–12. 30 indexed citations
16.
Kangas, Lauri, Merja Haaparanta‐Solin, Robert Paul, Dirk Roeda, & Hannu Sipilä. (1989). Biodistribution and Scintigraphy of 11C‐Toremifene in Rats Bearing DMBA‐Induced Mammary Carcinoma. Pharmacology & Toxicology. 64(4). 373–377. 14 indexed citations
17.
Sipilä, Hannu, et al.. (1988). Binding of Toremifene to Human Serum Proteins. Pharmacology & Toxicology. 63(1). 62–64. 20 indexed citations
18.
Vilpo, Juhani, et al.. (1987). Antileukemic activity against L1210 leukemia, pharmacokinetics and hematological side effects of 5-hydroxymethyl-2′-deoxyuridine. Leukemia Research. 11(10). 877–880. 8 indexed citations
19.
Kahlos, K., Lauri Kangas, & R. Hiltunen. (1986). Antitumor Activity of Triterpenes in Inonotus obliquus. Planta Medica. 52(6). 554–554. 20 indexed citations
20.
Kanto, J, et al.. (1979). Oral oxazepam as a premedicant in minor surgery.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 28(1). 36–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. De Coster Breakdown of academic impact, for papers by Seiichiro Tarui Breakdown of academic impact, for papers by Frederick R. DeRubertis Breakdown of academic impact, for papers by V.H.T. James Breakdown of academic impact, for papers by Yu‐Jui Yvonne Wan Breakdown of academic impact, for papers by Patricia A. Craven Breakdown of academic impact, for papers by Jamie D. Croxtall Breakdown of academic impact, for papers by Ruud Berger Breakdown of academic impact, for papers by Antonio Morelli Breakdown of academic impact, for papers by Alex Bobik
Rankless by CCL
2026